Ritholtz Wealth Management Invests $1.90 Million in Jazz Pharmaceuticals PLC (NASDAQ:JAZZ)

Ritholtz Wealth Management bought a new stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ - Free Report) in the 1st quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor bought 15,296 shares of the specialty pharmaceutical company's stock, valued at approximately $1,899,000.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in JAZZ. LSV Asset Management grew its stake in shares of Jazz Pharmaceuticals by 1.5% in the fourth quarter. LSV Asset Management now owns 2,531,050 shares of the specialty pharmaceutical company's stock worth $311,699,000 after acquiring an additional 37,108 shares during the last quarter. Dimensional Fund Advisors LP boosted its holdings in Jazz Pharmaceuticals by 18.7% in the 4th quarter. Dimensional Fund Advisors LP now owns 2,035,070 shares of the specialty pharmaceutical company's stock valued at $250,619,000 after purchasing an additional 320,724 shares during the period. Capital World Investors grew its position in Jazz Pharmaceuticals by 5.7% in the 4th quarter. Capital World Investors now owns 1,923,342 shares of the specialty pharmaceutical company's stock worth $236,860,000 after purchasing an additional 104,195 shares during the last quarter. Ameriprise Financial Inc. increased its stake in Jazz Pharmaceuticals by 20.9% during the fourth quarter. Ameriprise Financial Inc. now owns 1,827,658 shares of the specialty pharmaceutical company's stock valued at $225,076,000 after acquiring an additional 315,608 shares during the period. Finally, JPMorgan Chase & Co. raised its holdings in Jazz Pharmaceuticals by 4.8% in the 4th quarter. JPMorgan Chase & Co. now owns 1,587,541 shares of the specialty pharmaceutical company's stock valued at $195,506,000 after acquiring an additional 72,007 shares in the last quarter. Institutional investors and hedge funds own 89.14% of the company's stock.

Insider Buying and Selling at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, Director Seamus Mulligan bought 1,621 shares of the company's stock in a transaction on Monday, May 12th. The stock was bought at an average price of $103.00 per share, for a total transaction of $166,963.00. Following the transaction, the director now owns 101,621 shares of the company's stock, valued at approximately $10,466,963. The trade was a 1.62% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the firm's stock in a transaction on Tuesday, April 1st. The stock was sold at an average price of $123.75, for a total value of $185,625.00. Following the completion of the transaction, the chief executive officer now owns 440,307 shares in the company, valued at $54,487,991.25. This represents a 0.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last three months, insiders have sold 3,000 shares of company stock worth $355,925. Company insiders own 4.30% of the company's stock.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ traded down $0.58 during mid-day trading on Friday, hitting $107.66. 335,987 shares of the company traded hands, compared to its average volume of 830,845. The company has a current ratio of 3.38, a quick ratio of 2.97 and a debt-to-equity ratio of 1.28. The stock has a market capitalization of $6.51 billion, a price-to-earnings ratio of 14.36, a PEG ratio of 4.67 and a beta of 0.33. The business has a 50-day moving average of $108.00 and a 200 day moving average of $120.18. Jazz Pharmaceuticals PLC has a one year low of $95.49 and a one year high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last posted its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). The firm had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. Jazz Pharmaceuticals had a return on equity of 26.62% and a net margin of 11.86%. The firm's quarterly revenue was down .5% compared to the same quarter last year. During the same period in the prior year, the company posted $2.68 EPS. As a group, equities analysts expect that Jazz Pharmaceuticals PLC will post 16.96 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on JAZZ. Robert W. Baird decreased their price objective on Jazz Pharmaceuticals from $167.00 to $155.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Wall Street Zen cut shares of Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a research note on Thursday, May 15th. HC Wainwright increased their price target on shares of Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a "buy" rating in a research report on Monday, March 10th. UBS Group raised Jazz Pharmaceuticals from a "neutral" rating to a "buy" rating and lifted their price objective for the company from $145.00 to $179.00 in a report on Friday, March 7th. Finally, JPMorgan Chase & Co. upped their price objective on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the company an "overweight" rating in a research note on Wednesday, February 26th. Two investment analysts have rated the stock with a hold rating and twelve have given a buy rating to the company. Based on data from MarketBeat, Jazz Pharmaceuticals presently has a consensus rating of "Moderate Buy" and a consensus price target of $184.00.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.